News
SIBN
15.42
+0.78%
0.12
Notable Friday Option Activity: COIN, SIBN, DYN
NASDAQ · 9h ago
Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?
NASDAQ · 2d ago
Truist Financial Sticks to Their Buy Rating for SI-Bone (SIBN)
TipRanks · 2d ago
Is a Beat Likely for Intuitive Surgical (ISRG) in Q1 Earnings?
NASDAQ · 3d ago
SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024
SI-BONE, Inc. Will report financial results for the first quarter of 2024 after market close on May 6, 2024. Management will host a corresponding conference call. The company is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy.
Barchart · 4d ago
Weekly Report: what happened at SIBN last week (0408-0412)?
Weekly Report · 4d ago
U.S. RESEARCH ROUNDUP- Blackstone, Coupang, Wells Fargo
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Blackstone, Coupang, Wells Fargo & Co and Union Pacific raise their targets. 4D Molecular Therapeutics and Astera Labs are among the companies with new coverage on Monday.
Reuters · 4d ago
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 5d ago
Weekly Report: what happened at SIBN last week (0401-0405)?
Weekly Report · 04/08 12:06
SI-BONE Price Target Maintained With a $27.00/Share by Needham
Dow Jones · 04/03 15:47
Needham Reiterates Buy on SI-BONE, Maintains $27 Price Target
Benzinga · 04/03 15:34
SI-Bone’s Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth Prospects
TipRanks · 04/03 15:25
Weekly Report: what happened at SIBN last week (0325-0329)?
Weekly Report · 04/01 12:03
Peeling Back The Layers: Exploring SI-BONE Through Analyst Insights
SI-BONE (NASDAQ:SIBN) is a medical device company that develops and commercializes a minimally invasive surgical implant system. In the last three months, 4 analysts have published ratings on SI-BONES. The company has an average price target of $25.0. The average 12-month price target is a decline of 1.3% from the prior average.
Benzinga · 03/28 19:00
SI-BONE Price Target Announced at $25.00/Share by Piper Sandler
Dow Jones · 03/28 16:29
SI-BONE Initiated at Overweight by Piper Sandler
Dow Jones · 03/28 16:29
Weekly Report: what happened at SIBN last week (0318-0322)?
Weekly Report · 03/25 12:06
Weekly Report: what happened at SIBN last week (0311-0315)?
Weekly Report · 03/18 12:04
Si-Bone: Statement of changes in beneficial ownership of securities
Press release · 03/14 23:01
Buy Rating Affirmed for SI-Bone on Expansion and Market Growth Strategies
TipRanks · 03/13 10:38
More
Webull provides a variety of real-time SIBN stock news. You can receive the latest news about Si-Bone through multiple platforms. This information may help you make smarter investment decisions.
About SIBN
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.